NASDAQ:KERX Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free KERX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.97▼$3.4750-Day Range N/A52-Week Range$2.47▼$5.98Volume2.60 million shsAverage Volume1.69 million shsMarket Capitalization$344.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Keryx Biopharmaceuticals alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> KERX Stock News HeadlinesApril 13, 2024 | morningstar.comCaliway Biopharmaceuticals Co Ltd 6919November 15, 2023 | morningstar.comXTL Biopharmaceuticals Ltd ADR XTLBSeptember 11, 2023 | investing.comImmuneOnco Biopharmaceuticals Shanghai Inc (1541)August 13, 2023 | finance.yahoo.comQ2 2023 Westrock Coffee Co Earnings CallJuly 29, 2023 | thestreet.comKeryx CEO vs. a Short-Seller: Zerenex Patent DebateMay 12, 2023 | marketwatch.com8-K: CUTERA INCMay 6, 2023 | seekingalpha.comManoj MadhavanMay 3, 2023 | finance.yahoo.comBiopharmaceuticals Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand and ForecastApril 13, 2023 | wsj.comStaidson (Beijing) Biopharmaceuticals Co. Ltd.March 28, 2023 | finance.yahoo.comBiopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight PartnersJanuary 29, 2023 | marketwatch.comBiopharmaceuticals Market 2023 Analysis by Market Size, New Technology, Growth Rate, Geographical Regions, Drivers and Outlook to 2027January 25, 2023 | seekingalpha.comNAVB Navidea Biopharmaceuticals, Inc.January 25, 2023 | finance.yahoo.comBiopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)September 15, 2022 | thestreet.comWell-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug LaunchOctober 26, 2021 | finance.yahoo.comKeryx (KERX) Q1 Loss Wider than Expected, Revenues BeatJuly 29, 2021 | au.finance.yahoo.comTwitter tests notification banner for suspended and locked accountsJuly 29, 2021 | yahoo.comJoey Jordison, Slipknot co-founder and longtime drummer, dies at age 46July 28, 2021 | uk.finance.yahoo.comWhy Starbucks (SBUX) Might Surprise This Earnings SeasonJuly 27, 2021 | uk.finance.yahoo.comUN: World leaders can attend annual UN meeting in personJuly 27, 2021 | nz.finance.yahoo.comCreekstone Farms Meats Sizzle on Yoder Smokers With New PartnershipJuly 27, 2021 | au.finance.yahoo.comMidtown, Atlanta Based Innovien Solutions Continues Growth StreakJuly 27, 2021 | nz.finance.yahoo.comJill Biden Made This Versatile Bag Sell Out, and She Just Wore It AgainJuly 27, 2021 | yahoo.comIt's Your Business | More improvements on tap for Target on North ProspectSee More Headlines Receive KERX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2018Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:KERX CUSIP49251510 CIK1114220 Webwww.keryx.com Phone617-466-3500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,440,000.00 Net Margins-96.41% Pretax MarginN/A Return on EquityN/A Return on Assets-60.05% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.19 Sales & Book Value Annual Sales$60.64 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-28.00Miscellaneous Outstanding Shares102,380,000Free FloatN/AMarket Cap$344.00 million OptionableOptionable Beta2.35 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 43)Interim CEO & Director Mr. Scott A. Holmes (Age 44)CFO, Sr. VP & Treasurer Ms. Christine A. Carberry (Age 57)Sr. VP & COO Dr. John F. Neylan (Age 65)Sr. VP & Chief Medical Officer Mr. Tony ChambersVP of SalesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXMannKindNASDAQ:MNKDInnovivaNASDAQ:INVAIronwood PharmaceuticalsNASDAQ:IRWDOPKO HealthNASDAQ:OPKView All Competitors KERX Stock Analysis - Frequently Asked Questions How were Keryx Biopharmaceuticals' earnings last quarter? Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $28.04 million for the quarter, compared to analyst estimates of $29.56 million. What other stocks do shareholders of Keryx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Akebia Therapeutics (AKBA), Ariad Pharmaceuticals (ARIA), Chesapeake Energy (CHKAQ) and Celldex Therapeutics (CLDX). This page (NASDAQ:KERX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keryx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keryx Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.